Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06973720 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
A Phase 2 study of Obesity and Overweight or Obesity, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 5
- Study locations
NCT06973720 is a Phase 2 study of Obesity and Overweight or Obesity that is active but no longer recruiting, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT06973720, a Phase 2 study of Obesity and Overweight or Obesity, is active but no longer recruiting, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MET097
Study Locations (5)
Florida
- Research Site 097203-001001 - Hollywood
- Research Site 097203-001003 - Tampa
Georgia
- Research Site 097203-001002 - Decatur
- Research Site 097203-001005 - Savannah
New Jersey
- Research Site 097203-001004 - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06973720
The ClinicalTrials.gov registry entry for NCT06973720 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The listed sponsor is Metsera, a wholly owned subsidiary of Pfizer, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06973720 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, Georgia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06973720 about?
NCT06973720 is a clinical study titled "A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight". This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.
What is the current status of trial NCT06973720?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-04-01. Estimated completion is 2026-10.
What conditions does trial NCT06973720 study?
This clinical trial studies the following conditions: Obesity, Overweight or Obesity.
What interventions are being tested in trial NCT06973720?
The interventions under investigation include: Placebo (DRUG), MET097 (DRUG).
Who is sponsoring clinical trial NCT06973720?
This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06973720 being conducted?
This trial has 5 study locations across Florida, Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.